Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues.
Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds.
Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
Vd Andreas Bhagwani berättar om Nanologica och den pågående företrädesemissionen.
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
Teckningsperioden i Nanologicas företrädesemission inleds 11 mars och pågår till och med 25 mars. Teckning med stöd av företrädesrätt Teckning av aktier med stöd av teckningsrätter sker genom samtidig kontant betalning under perioden från och med den 11 mars 2026 till och med den 25 mars 2026. Observera att det kan ta upp till tre
The nomination committee of Nanologica proposes to the Annual General Meeting on May 21 that Mark Quick and Erik Haeffler be elected as new members of the board of directors of Nanologica AB. Furthermore, Thomas Eldered is proposed as new chairman of the board. Mark Quick works as a Partner at Flerie AB having previously
Nanologica AB (publ) (”Nanologica” or ”the Company”) hereby announces the outcome of the two directed issues of shares resolved by the board of directors on 30 January 2026 and approved by the extraordinary general meeting on 4 March 2026. The directed issues comprised a total of 34,203,780 shares. All shares have been subscribed for and
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
Vd Andreas Bhagwani berättar om Nanologica och den pågående företrädesemissionen.
For more videos presentations of the company and of interim reports, please refer to Investor Relations.
CEO Andreas Bhagwani presents at Redeye Theme Event Tools and Supplies in Life Science September, 2025.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
